CORZ
Core Scientific, Inc./txCore Scientific, Inc./tx reported revenue of $319.02M in its most recent fiscal year, down 37.5% on the year before. It kept -90.5% of that as net income, and generated -$450.75M of free cash flow. Figures below are compared against other companies classified under Finance Services.
Grades vs. industry
Growth
| Metric | Company | Industry median | Rank |
|---|---|---|---|
Revenue growth (YoY) Latest fiscal year revenue vs. the year before. | -37.5% | 10.8% | 87 / 93 |
Revenue growth (3y) Annualized revenue growth over three fiscal years. | -20.7% | 9.3% | 64 / 76 |
Revenue growth (5y) Annualized revenue growth over five fiscal years. | 39.5% | 18.2% | 21 / 59 |
EPS growth (YoY) Diluted EPS vs. the prior fiscal year. | Not reported | -55.3% | — |
EPS growth (3y) Annualized diluted EPS growth over three fiscal years. | Not reported | 14.7% | — |
EPS growth (5y) Annualized diluted EPS growth over five fiscal years. | Not reported | 17.0% | — |
Free cash flow growth (YoY) Operating cash flow less capital expenditure, vs. prior year. | Not reported | -6.8% | — |
Free cash flow growth (3y) Annualized free cash flow growth over three fiscal years. | Not reported | 11.2% | — |
top third of peersmiddle thirdbottom third. Rank 1 is always best — for debt and payout ratios that means the lowest figure, not the highest.
“Not reported” means the company did not tag this figure in its filing, not that the value is zero. Rankings are hidden where fewer than 5 classified peers reported the metric, and compare against a broad industry code rather than close competitors.
Profitability
| Metric | Company | Industry median | Rank |
|---|---|---|---|
Gross margin Gross profit as a share of revenue. Often unreported. | 11.9% | 39.2% | 39 / 59 |
Operating margin Operating income as a share of revenue. | -77.0% | -53.0% | 41 / 68 |
Net margin Net income as a share of revenue. | -90.5% | -31.2% | 60 / 91 |
Free cash flow margin Free cash flow as a share of revenue. | -141.3% | -21.2% | 55 / 65 |
Return on equity Net income divided by shareholder equity. | Not reported | -13.7% | — |
Return on assets Net income divided by total assets. | -12.3% | -8.1% | 59 / 102 |
Return on invested capital After-tax operating profit over debt plus equity less cash. | Not reported | -13.0% | — |
top third of peersmiddle thirdbottom third. Rank 1 is always best — for debt and payout ratios that means the lowest figure, not the highest.
“Not reported” means the company did not tag this figure in its filing, not that the value is zero. Rankings are hidden where fewer than 5 classified peers reported the metric, and compare against a broad industry code rather than close competitors.
Financial health
| Metric | Company | Industry median | Rank |
|---|---|---|---|
Debt to equity Total debt divided by shareholder equity. | Not reported | 0.48x | — |
Current ratio Current assets over current liabilities. | 1.15x | 1.92x | 54 / 73 |
Quick ratio Current assets excluding inventory, over current liabilities. | 1.15x | 1.92x | 54 / 73 |
Interest coverage Operating income divided by interest expense. | Not reported | -10.71x | — |
Net debt to EBITDA Net debt over derived EBITDA. EBITDA is not a GAAP tag; it is computed. | Not reported | -0.59x | — |
top third of peersmiddle thirdbottom third. Rank 1 is always best — for debt and payout ratios that means the lowest figure, not the highest.
“Not reported” means the company did not tag this figure in its filing, not that the value is zero. Rankings are hidden where fewer than 5 classified peers reported the metric, and compare against a broad industry code rather than close competitors.
Insider activity
Trades reported by officers, directors and 10% shareholders on SEC Form 4. 3 of the last 28 reported transactions were open-market purchases; the rest are mostly sales and compensation.
| Date | Insider | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Oct 19, 2026 | DUCHENE TODD M See remarks | Open-market sale | 10,000 | $13.87 | $138.7K |
| Oct 16, 2026 | Sullivan Adam Taylor Chief Executive Officer | Withheld for tax | 21,839 | $14.46 | $315.7K |
| Oct 16, 2026 | DUCHENE TODD M See remarks | Withheld for tax | 6,382 | $14.46 | $92.3K |
| Oct 12, 2026 | DUCHENE TODD M See remarks | Open-market sale | 10,000 | $15.12 | $151.2K |
| Oct 5, 2026 | DUCHENE TODD M See remarks | Open-market sale | 10,000 | $16.31 | $163.1K |
| Oct 1, 2026 | Sullivan Adam Taylor Chief Executive Officer | Withheld for tax | 23,508 | $15.98 | $375.7K |
| Oct 1, 2026 | DUCHENE TODD M See remarks | Withheld for tax | 8,228 | $15.98 | $131.5K |
| Sep 28, 2026 | DUCHENE TODD M See remarks | Open-market sale | 10,000 | $16.76 | $167.6K |
| Sep 21, 2026 | DUCHENE TODD M See remarks | Open-market sale | 10,000 | $18.37 | $183.7K |
| Sep 15, 2026 | Weiss Eric Stanton Director | Open-market purchase | 6,000 | $16.33 | $98.0K |
| Sep 14, 2026 | DUCHENE TODD M See remarks | Open-market sale | 10,000 | $17.14 | $171.4K |
| Sep 9, 2026 | DUCHENE TODD M See remarks | Gift(derivative) | 95,000 | $0.00 | $0.00 |
| Sep 8, 2026 | DUCHENE TODD M See remarks | Open-market sale | 10,000 | $18.67 | $186.7K |
| Aug 31, 2026 | DUCHENE TODD M See remarks | Open-market sale | 10,000 | $16.23 | $162.3K |
| Aug 24, 2026 | DUCHENE TODD M See remarks | Open-market sale | 10,000 | $17.45 | $174.5K |
| Aug 20, 2026 | CRAIN ELIZABETH Director | Open-market purchase | 6,000 | $18.33 | $110.0K |
| Aug 18, 2026 | Weiss Eric Stanton Director | Open-market purchase | 7,000 | $19.19 | $134.4K |
| Aug 17, 2026 | DUCHENE TODD M See remarks | Withheld for tax | 11,205 | $20.13 | $225.6K |
| Aug 17, 2026 | DUCHENE TODD M See remarks | Open-market sale | 10,000 | $20.10 | $201.0K |
| Aug 10, 2026 | DUCHENE TODD M See remarks | Open-market sale | 9,000 | $19.90 | $179.1K |
| Aug 10, 2026 | DUCHENE TODD M See remarks | Open-market sale | 1,000 | $20.65 | $20.6K |
| Aug 3, 2026 | DUCHENE TODD M See remarks | Open-market sale | 7,500 | $22.62 | $169.6K |
| Aug 3, 2026 | DUCHENE TODD M See remarks | Open-market sale | 1,500 | $21.55 | $32.3K |
| Aug 3, 2026 | DUCHENE TODD M See remarks | Open-market sale | 1,000 | $20.39 | $20.4K |
| Jul 30, 2026 | Adams Mark Director | Grant or award | 27,594 | $0.00 | $0.00 |
A dash under price or value means none was reported, which is normal for grants and gifts — it does not mean the shares were free. Option exercises and awards are compensation arriving on a schedule, not a judgement about the stock.
Annual financials
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Revenue | $319.02M | $510.67M | $502.40M | $640.31M | $544.48M | $60.32M |
| Gross profit | $37.90M | $121.07M | $123.46M | $8.40M | $238.86M | $9.39M |
| Operating income | -$245.59M | -$142.06M | $8.96M | -$2.11B | $131.49M | -$6.33M |
| Net income | -$288.62M | -$1.44B | -$246.49M | -$2.15B | $47.31M | -$12.21M |
| EPS (diluted) | -$0.88 | -$4.87 | -$0.65 | -$6.30 | $0.20 | -$0.14 |
| Operating cash flow | $278.25M | $42.90M | $65.11M | $205.19M | -$56.73M | -$23.77M |
| Capital expenditure | $729.00M | $94.96M | $16.16M | $383.98M | $0.00 | $0.00 |
| Free cash flow | -$450.75M | -$52.06M | $48.95M | -$178.79M | -$56.73M | -$23.77M |
| Total assets | $2.35B | $1.48B | $712.16M | $807.69M | $2.44B | $15.0K |
| Shareholder equity | -$962.74M | -$943.05M | -$596.94M | -$409.35M | $1.34B | $89.22M |
| Total debt | $1.06B | — | — | — | — | — |
| Cash | $311.38M | $836.20M | $50.41M | $15.88M | $117.87M | $8.72M |
A dash means the figure was not tagged in that year’s filing. It does not mean zero. Figures reflect the most recent filing covering each period, so restated years show their restated values.
Source
Figures come from Core Scientific, Inc./tx’s filings with the SEC, as submitted in XBRL. The most recent annual figures are from a 10-K filed Mar 2, 2026. View filings on EDGAR.